


amfAR

MAKING AIDS HISTORY



HIV

COVID-19

2020

ANNUAL REPORT

amfAR, The Foundation for AIDS Research


OUR MISSION:

amfAR, The Foundation for AIDS Research, is dedicated to ending the global AIDS epidemic through innovative research.

CONTENTS

| | |
|---|-----------|
| Progress in the Face of a New Pandemic | 01 |
| Research | 01 |
| Public Policy | 04 |
| TREAT Asia | 06 |
| Public Information | 07 |
| Grants, Fellowships, and Awards | 09 |
| Research Grants, Fellowships, and Awards | 09 |
| TREAT Asia Grants and Awards | 10 |
| Financial Highlights | 13 |
| Leadership and Advisory Committees | 15 |
| Board of Trustees | 15 |
| Scientific Advisory Committee | 15 |
| Program Advisory Council | 19 |
| Management Group | 19 |

PROGRESS IN THE FACE OF A NEW PANDEMIC



SARS-CoV-2, the virus that causes COVID-19

RESEARCH ▼

amfAR Fund to Fight COVID-19

Temporarily expanding its efforts to include research on the novel coronavirus, in April 2020 amfAR established the **amfAR Fund to Fight COVID-19**, announcing its first COVID grants in July.

- ▶ A common and often deadly consequence of advanced COVID-19 disease is acute kidney injury. Cells in the kidney express the ACE2 protein, which serves as a receptor for the virus and may underlie the kidney damage. Dr. Matthias Kretzler of the University of Michigan, Ann Arbor, was awarded \$155,650 to use a clever technique to understand what happens in the kidney of those with COVID-19. By comparing patients receiving anti-inflammatory treatment to those who were not, Dr. Kretzler aimed to develop a tool to predict who would most benefit from this kind of treatment.
- ▶ A second grant of \$192,000 was awarded to Dr. Daniel Kaufmann of the University of Montreal for a study of antibody responses to COVID-19. Dr. Kaufmann was able to tap into the Quebec COVID-19 Biobank, established at the beginning of the pandemic to collect biological samples from patients admitted to the hospital. These banked samples, collected from the time of admission through several months of follow-up, allowed Dr.

Kaufmann and his team to study why some people develop antibodies and others do not, how we can predict whether those antibodies protect against reinfection, and how long the protection lasts.

Countdown to a Cure for AIDS

To accelerate the search for a cure, in 2015 amfAR launched its Countdown to a Cure for AIDS initiative. To date, 87 grants totaling more than \$50 million have been awarded through the Countdown, supporting research conducted by 300 scientists working at more than 100 institutions in 16 countries. Structured to provide sustained support for a range of studies that advance both emerging and established ideas, the Countdown comprises the following components:

- ▶ **The amfAR Institute for HIV Cure Research** was established in 2015 with a \$20 million grant over five years to the University of California, San Francisco (UCSF). Researchers at the Institute have been laying the groundwork for a complex clinical study employing a three-pronged approach to eradicating HIV. A therapeutic vaccine is combined with an immune adjuvant—a drug often used to boost the efficacy of vaccines—that has been shown in clinical trials to have additional anti-HIV effects. The third component combines two broadly neutralizing antibodies,

the source of much optimism in the cure field for their ability not only to kill viruses that are produced by infected cells, but also to direct the immune system to kill the very cells producing those viruses. In August 2020, the trial got underway when the first injection was given to the first participant.

- ▶ **ARCHE, the amfAR Research Consortium on HIV Eradication**, supports collaborative teams of scientists in the U.S. and around the world working on a range of HIV cure strategies. For several years, amfAR's ARCHE-GT consortium has been designing and fine-tuning three gene therapy approaches to curing HIV that could be delivered in vivo—directly to the patient.

One approach involves the generation of chimeric antigen receptor (CAR) stem cells that are designed specifically to kill virus-infected cells. A second is to spur liver cells to produce HIV-specific antibodies. The third is to deliver an enzyme that would edit the virus out of infected cells. Each of these three tools is now ready to be tested in combination.

In February 2020, Dr. Hildegard Büning of Hannover Medical School, Germany, was awarded \$1.65 million for a preclinical study to test their effectiveness. This complex gene therapy study will provide vital signposts informing further curative gene therapy studies.

- ▶ **Uniting data scientists with HIV researchers, one-year Magnet Grants** of up to \$150,000 are harnessing advances in machine learning algorithms to find patterns in the vast trove of data researchers have amassed over the past decade. Already a critical component of the success of precision medicine, machine learning is able to identify patterns in health and disease that we wouldn't know to look for. In February 2020, amfAR awarded grants totaling about \$600,000 to research teams in the U.S., Australia, and Brazil.


The HIV reservoir may expand when infected T cells grow in number to fight invading pathogens. Identifying how to limit expansion in reservoir cells while maintaining normal expansion

in uninfected T cells would be an important step toward a cure. Magnet grantee Dr. Ya-Chi Ho has collected vast amounts of data on the activity of over 133,000 T cells, including rare reservoir cells, across seven people living with HIV. With the help of bioinformatician Dr. David van Dijk, the team is building machine-learning tools to identify mediators of T cell expansion that affect reservoir cells specifically.

Collaborating with data scientists Drs. Doron Betel and Friederike Dundar, Dr. Brad Jones aims to identify, using public and private datasets, differences between reservoir cells that survived attack by the immune system and those that were susceptible. Then the researchers will analyze cancer datasets to determine whether those protective factors identified in HIV are also present in cancer—a disease that may have FDA-approved drugs to target those factors.

By understanding exactly where HIV inserts itself in our genome, researchers can make inferences about how location may predict latency. Dr. Sharon Lewin, a world-renowned HIV cure researcher, has teamed up with Dr. Daniel Cameron, a former software developer turned academic bioinformatician, to develop a data science mapping pipeline to chart the hard-to-reach areas of our genome. Using over 600GB of cloud computing memory and mining 30 public and private datasets, the researchers aim to gain a more complete understanding of what insertion site means for HIV latency—and ultimately cure.

- ▶ **Synergy Grants** capitalize on unforeseen possibilities for collaboration and enable us to add new study arms onto existing amfAR grants. In February 2020, amfAR awarded \$50,000 to Dr. Jonathan Li of The Brigham and Women's Hospital in Boston. In 2019, amfAR launched Project PTC, the largest study to date aimed at discovering the underpinnings of post-treatment control—viral control in the absence of antiretroviral therapy (ART). Led by Dr. Li, one of the world's leading PTC researchers, the team has been using cutting-edge tools to explore immune control and viral dynamics. The new grant recruited Dr. Michael Seaman, an expert in HIV antibody responses at Harvard Medical School. This additional expertise could help determine whether antibodies help shape the ability of PTCs to control virus once they stop taking ART. Discovering what leads to post-treatment control in these rare individuals could help in designing methods to achieve durable ART-free control in all people living with HIV.




amfAR grantee Dr. Brad Jones

Mathilde Krim Fellowships in Basic Biomedical Research

These fellowships support bright young scientists advancing innovative solutions to HIV/AIDS. In December 2019, amfAR announced two new Krim Fellows: Dr. Maolin Lu of Yale University in New Haven, CT, and Dr. Shaheed Abdulhaqq, of Oregon Health and Science University in Portland, OR. Each fellow is awarded approximately \$150,000 over two years.

COVID-19 Pause

Due to the COVID-19 pandemic, in March 2020 amfAR temporarily paused its ongoing HIV research grants with the exception of one



grant funded by the FAIR Foundation. The pause ended on July 1, 2020, for a clinical trial at the amfAR Institute for HIV Cure Research in San Francisco, and October 1 for other paused research.

Published Research

Research studies make the greatest impact on the HIV field and on the broader scientific community when they are published in scientific journals. In FY2020, 80 scientific publications resulted from amfAR-funded research. Examples include:

- ▶ **Seeing Is Believing: Nuclear Imaging of HIV Persistence**
In Frontiers in Immunology, Dr. Timothy Henrich of the amfAR Institute for HIV Cure Research and colleagues outlined a cutting-edge technique using the only EXPLORER PET scanner currently operational in the U.S. to visualize the places where HIV resides in host tissue cells. The machine is able to produce images that are approximately 40 times more sensitive than current technology in a fraction of the time. The technology may help researchers identify which tissues are responsible for HIV resurgence following treatment interruption as part of a cure intervention.

- ▶ **Attacking Latent HIV with Convertible CAR T Cells, a Highly Adaptable Killing Platform**
 In the prestigious journal *Cell*, members of the amfAR Institute for HIV Cure Research reported the development of a new type of CAR T cell—one that can keep up with HIV’s ever mutating envelope. Convertible CAR T cells can target multiple strains of HIV without the need to manufacture as many different CAR T cells as there are strains. Harnessing the ability of this new platform to selectively kill HIV-infected cells, researchers may be able to develop more effective cure strategies in which latency-reversing agents reactivate latent HIV.

HIV Cure Summit

In November 2019, amfAR held its sixth annual HIV Cure Summit at the University of California, San Francisco (UCSF), where the amfAR Institute for HIV Cure Research is based. Leading amfAR-funded cure researchers detailed their progress and discussed the scientific challenges that continue to stand in the way of a cure. Dr. Rachel Rutishauser, for example, outlined the pioneering clinical trial at the Institute that will test a combination approach to curing HIV (see page 1).

Dr. Rowena Johnston, amfAR Vice President and Director of Research, discussed “societies of research,” displaying a visualization tool to show how in recent years HIV researchers are collaborating more than ever before. Speaking with Dr. Johnston, Loreen Willenberg, the “San Francisco patient,” shared her inspiring personal story, from her HIV diagnosis in 1992 to recognition by her doctors that she was somehow able to maintain undetectable viral levels without ever taking ART, to being an invaluable participant in HIV studies for over a decade.

Discussing post-treatment control of HIV, Drs. Peter Hunt of UCSF and Marcella Flores of amfAR outlined efforts to study the rare individuals—post-treatment controllers—who are able to naturally control their virus after stopping ART. A better understanding of how these individuals are able to do so could help researchers induce post-treatment control in other people living with HIV.

The Summit also featured a range of perspectives from members of the community advisory board for the amfAR Institute and other community leaders.

Informed by thorough research and analysis, amfAR is a highly respected advocate of rational and compassionate HIV/AIDS-related public policy. The Foundation is engaged in efforts to secure necessary increases in funding for HIV/AIDS research and global HIV/AIDS programs, expand access to treatment and care for marginalized populations, advocate harm reduction policies aimed at reducing the spread of HIV and hepatitis C (HCV) among people who inject drugs, and protect the civil rights of all people affected by or vulnerable to HIV/AIDS.

Ending the Domestic HIV Epidemic

In 2019, President Trump announced a plan to end HIV transmissions in the U.S. by 2030. *The Ending the HIV Epidemic* (EHE) initiative aims to reduce HIV infections by 75% in five years, and by 90% in ten years. In 2019, amfAR launched a free interactive database (ehe.amfar.org) to help policymakers, public health officials, advocates, and other stakeholders understand the opportunities and challenges across EHE jurisdictions. The EHE database includes demographic, policy, and service provider information, and epidemiological indicators.

In October 2019, amfAR published *Context Matters: Ending the HIV Epidemic Among Latinx*, an infographic showing how lack of access to healthcare, along with the Trump administration’s anti-immigrant rhetoric and policies, make it unlikely that the EHE initiative will succeed. A second infographic depicted the stark racial disparities in the epidemiology of HIV and access to care in the U.S.

In February, amfAR Vice President and Director of Public Policy Greg Millett penned an op-ed for *Healio’s* Infectious Disease News that argued for HIV prevention programs tailored to Black Americans. This was followed by a Millett op-ed in *The Hill* on progress and setbacks a year into the EHE initiative.

Since the implementation of the Affordable Care Act (ACA) in 2010, millions of Americans including people living with HIV have benefited from expanded access to healthcare. On the tenth anniversary of the ACA being signed into law, in March 2020, amfAR published a report showing with charts and graphics the progress that has been achieved by the ACA and what could be lost due to Congress and President Trump undermining the policy. In particular, the report showed how the ACA could benefit Trump’s effort to end the HIV epidemic through his EHE plan.

The COVID-19 Pandemic

In May 2020, amfAR released study results that were among the first to quantify disparities in impacts of the coronavirus pandemic. The study revealed that disproportionately Black counties—representing about one in five U.S. counties—accounted for 52% and 58% of COVID-19 cases and deaths, respectively. It also countered the narrative that underlying health conditions were responsible for disparate rates of SARS-CoV-2 diagnoses among Black Americans. Instead, social factors such as high rates of uninsured and crowded households in Black counties were responsible for greater rates of

COVID-19. The study generated significant national media attention. Published in *Annals of Epidemiology* in July 2020, it has been cited in more than 100 publications including the *New England Journal of Medicine* and *JAMA*.

Also in July, a study by a multi-institutional team led by researchers at The George Washington University found that factors linked to structural racism put Latino communities nationwide at high risk of COVID-19. amfAR’s Greg Millett was senior author on the study. The researchers detailed contributing factors including crowded housing, air pollution and jobs in the meatpacking and poultry industry. The first national analysis of COVID deaths and cases among this group, it confirmed previous reports that Latinos were particularly hard hit by the virus.


In August, an amfAR study showed that disproportionately white counties in the U.S. had consistently lower rates of COVID-19 and HIV. Residential segregation, structural racism, and social determinants of health were noted as key factors driving diagnoses in nonwhite communities. With schools reopening in some states, the amfAR study suggested that comparatively higher COVID-19 diagnoses in non-white counties placed youth and adults in those counties at greater risk for infection.

As a companion resource for these studies on disparities, amfAR launched a new data dashboard tracking COVID-19 cases and diagnoses in U.S. counties with a large proportion of racial/ethnic minorities.

Context Matters: Ending the HIV Epidemic Among Latinx

The federal government’s Ending the HIV Epidemic (EHE) plan has the goal of reducing new HIV infections by 90% in the next 10 years. This goal will not be met without eliminating disparities in access to services in the Latinx community. The current administration’s anti-immigrant rhetoric and policies make this unlikely to happen.

Non-citizens and undocumented individuals will be less likely to seek testing, prevention, or treatment services if they fear deportation and arrest, or loss of the opportunity to someday become citizens. And their families and communities may also be less likely to access services in order to protect themselves and undocumented people in their community. These policies directly undermine any efforts in the EHE plan to improve access to services among the Latinx community.



What's Helping?

- Ending the HIV Epidemic (EHE) plan**
 - 90% targeted decrease in HIV infections by 2030
 - 48 countries, plus Washington, D.C. and San Juan, PR.
 - 7 states

What's Not?

Several administration actions directly undercut any efforts in the EHE plan to improve access to services among the Latinx community.

- Demonization of immigrants and Latinx**
Leads to increased stigma, real and feared, preventing groups from accessing services
- Fear of arrest and deportation**
Prevents Latinx, especially the undocumented and their families, from accessing services
- Public charge rule**
Drives noncitizens to avoid using public benefits including health services
- Federal immigration restrictions**
Restrictions prevent immigrants who do not have health insurance from entering legally

One of a series of infographics illustrating priority issues for amfAR’s Public Policy Office.

Also in August, amfAR published an issue brief on gender-based violence (GBV) in South Africa during the coronavirus pandemic. The analysis found significant barriers to service availability and called for government action and resources to be directed to ensure reliable access to GBV services for the duration of COVID-19 and beyond.

amfAR also published several op-eds early in the pandemic. In February 2020, amfAR Senior Policy and Medical Advisor Dr. Susan Blumenthal penned an op-ed for *The Hill* outlining five ways to prepare for the coronavirus. In March she wrote for *The Advocate* on the essential lessons from the AIDS epidemic that could be applied to the COVID-19 crisis, followed by two op-eds in April: one in *Thrive Global* argued that young people held the key to “flattening the curve,” and the other, for CNN, made the case for studying the effects of COVID on women.

HIV and the Opioid Epidemic

amfAR’s Opioid & Health Indicators Database (opioid.amfar.org) is a free web platform designed to support lawmakers, communities, and advocates in making informed decisions about the opioid epidemic and its impact on HIV and hepatitis C. It provides local to national statistics using reliable data sources on new HIV and hepatitis C infections, opioid use and overdose death rates, and the availability of services like drug treatment programs and syringe exchange services.

Advocating on the Global Stage

In November 2019, amfAR published an issue brief outlining the impacts of the “global gag rule” for the Global Fund to Fight AIDS, Tuberculosis and Malaria. Reinstated and expanded by President Trump in 2017 [and subsequently rescinded by the Biden administration], the policy restricted non-U.S.-based or foreign NGOs from receiving American financial aid if they perform, counsel on, or refer for abortion, or advocate for its liberalization outside of limited exceptions. The issue brief concluded that the policy was linked to “disruptions in HIV programming—including basic HIV prevention services such as condom distribution, HIV testing, and voluntary medical male circumcision programming to prevent HIV.”

amfAR maintains the PEPFAR Monitoring, Evaluation, and Reporting database (mer.amfar.org). Launched in 2018, the database enables policymakers, public health officials, advocates, and other stakeholders to access a wide range of programmatic data on PEPFAR (the U.S. President’s Emergency Plan for AIDS Relief) and includes downloadable PDFs, maps, data visualizations, and district-level data. The database complements amfAR’s PEPFAR database (copsdata.amfar.org), which highlights planned funding by program area, country and organization for each year that has been publicly released.

In October 2019, amfAR published a 20-page report titled *Data Watch: Data Accessibility from Global Funders of HIV, TB and Malaria Programming*. The report assessed the adequacy of information regarding who is being funded in a given community, what they have been funded to do, and whether they have delivered as contracted.

AIDS 2020

amfAR’s Public Policy Office participated in the biennial International AIDS Conference—the premier global meeting for the HIV field—July 6-10. Delegates came together virtually to hear about and discuss the latest HIV research findings and policy issues, and intersections with the coronavirus.

Public Policy Director Greg Millett delivered an opening plenary talk that contextualized 40 years of disparities throughout the HIV pandemic, and joined a live Q&A session with Dr. Linda-Gail Bekker of the Desmond Tutu HIV Centre at the University of Cape Town, former president of the International AIDS Society.

amfAR’s Deputy Director of Public Policy Brian Honermann presented at a virtual community workshop that focused on the effective use of data tools to drive impactful change in the HIV response. And Policy Associate Jennifer Sherwood gave a symposium talk on whether current approaches to collecting data capture the full impact of HIV on women.

The conference featured many talks on the intersection of HIV and COVID-19. Greg Millett joined Merck Vice President of Social Innovation Carmen Villar for a “fireside chat” to discuss a paper Millett co-authored assessing the differential impacts of COVID-19 on black communities. Millett also joined Chris Collins of Friends of the Global Fight and others in a session titled *How did they do it? What successful communities can teach all of us about making dramatic progress against HIV epidemics and what this means in the age of COVID*. The session was a one-year follow-up to a report co-authored by amfAR, AVAC and Friends of the Global Fight titled *Translating Progress into Success to End the AIDS Epidemic*.



amfAR VP and Director of Public Policy Greg Millett delivered an opening plenary address at AIDS 2020, the virtual International AIDS Conference.

TREAT ASIA

amfAR's TREAT Asia (Therapeutics Research, Education, and AIDS Training in Asia) program is a network of hospitals, clinics, and research institutions working with civil society to ensure the safe and effective delivery of treatments for HIV and its co-infections to adults and children across the Asia-Pacific through research, education, and advocacy. The TREAT Asia Network encompasses 21 adult and 20 pediatric sites throughout the region, which collaborate on a variety of projects. TREAT Asia scientists produced 33 publications in peer-reviewed medical journals in 2020.

Gathering Critical Information

TREAT Asia pioneered the region's first adult observational database for HIV/AIDS, which now includes anonymous data from nearly 10,000 patients at 21 clinical sites in 12 countries. The TREAT Asia HIV Observational Database (TAHOD) gathers information to inform the development of more effective research and treatment programs and helps define treatment standards specific to HIV/AIDS in Asia. The TAHOD-LITE database, an extension of TAHOD, contains data from over 37,000 HIV-positive patients across ten TREAT Asia network sites and aims to increase the scope of adult data collection by gathering a subset of core variables from all HIV-infected patients who have sought care at selected TAHOD sites.

A Global Collaboration

In partnership with the Kirby Institute at the University of New South Wales, TREAT Asia manages the Asia-Pacific section of the International epidemiology Databases to Evaluate AIDS (IeDEA), a global collaboration established by the U.S. National Institute of Allergy and Infectious Diseases.

Improving Care for Children

The TREAT Asia Pediatric HIV Observational Database is a regional pediatric HIV study set up by TREAT Asia in 2006. It was modeled on the adult database and includes data from more than 7,400 children and adolescents at 17 clinical sites in Cambodia, India, Indonesia, Malaysia, Thailand, and Vietnam.

Integrating HIV, Mental Health, and Implementation Science Research

In 2019, the U.S. National Institutes of Health awarded a five-year, \$1.4 million grant to TREAT Asia and Columbia University to establish an innovative platform for integrating HIV, mental health,



TREAT Asia's regional network spans more than 50 research institutions and community organizations in 13 countries across the Asia-Pacific region.

and implementation science research in the Asia-Pacific region. The objective of the CHIMERA program (**C**apacity development for **HIV** and **m**ental health research in **A**sia) is to address the dual and interlinked burdens of HIV and mental health. Co-led by Principal Investigators Dr. Annette Sohn, amfAR vice president and director of TREAT Asia, and Dr. Milton Wainberg, professor of clinical psychiatry at Columbia University and the New York State Psychiatric Institute, the program aims to build a team within the Asia-Pacific with the capacity to lead regional HIV-mental health-implementation science research that will inform public health policy and improve the quality of clinical care for people living with HIV.

The program is nested within the IeDEA (see above) Asia-Pacific regional research network that TREAT Asia directs. CHIMERA creates the opportunity to bring together stellar training faculty from academic centers and public health and development agencies within the region and across the world, and builds on existing NIH-funded mental health research being conducted through IeDEA Asia-Pacific.

In February 2020, a workshop for CHIMERA fellows was held in Bangkok, covering implementation science frameworks and study designs, informatics for research and public health, and the responsible conduct of research. Fellows also met with TREAT Asia and faculty to discuss their pilot research proposals.

The COVID-19 Pandemic

In April 2020, TREAT Asia led the submission of a letter to the Regional Directors of World Health Organization (WHO) South-East

Asia and Western-Pacific. Signed by 32 regional and national civil society organizations, the letter called for WHO to play a greater role in ensuring continuity of HIV-related healthcare services during the COVID-19 public health emergency in the Asia-Pacific.

TREAT Asia is collaborating with the Institute of HIV Research and Innovation (IHRI), Thai Red Cross AIDS Research Center (TRC-ARC) laboratory, and the NIH Vaccine Research Center to conduct SARS-CoV-2 serologic assays of Thai adults taking and not taking antiretroviral drugs for pre-exposure prophylaxis and treatment of HIV. In September 2020, more than 1,800 samples were sent to the National Institutes of Health.

Throughout the year, TREAT Asia participated in various meetings held virtually with organizations and community members from countries throughout the Asia-Pacific region to navigate the impacts of COVID-19 on critical HIV and hepatitis services and initiatives.

Helping Adolescents Transition to Adult Care

More than one in four new HIV infections in the Asia-Pacific occur in young people aged 15–24 years. Continuing its commitment to helping adolescents transition to adult care, in 2019 TREAT Asia initiated plans for a study of adolescents and young adults living with HIV. A total of 75 HIV-disclosed adolescents with HIV were enrolled from three participating sites in Thailand and the Philippines for initial and 12-month follow-up assessments. Critical outcomes including viral suppression, treatment adherence, pregnancy, and mortality will be assessed.



AIDS 2020

Asia had a strong presence at the 23rd International AIDS Society Conference (AIDS 2020) held virtually in July. TREAT Asia Director Dr. Annette Sohn moderated a prime session Q&A on pediatric HIV along with Martina Penazzato of the World Health Organization. Dr. Sohn also spoke at a workshop addressing the essential skill for early-career HIV researchers of writing and successfully submitting scientific papers to peer-reviewed journals. Numerous TREAT Asia partner investigators and affiliates also gave poster presentations at the conference.

TREAT Asia also participated in the fifth Asia Pacific AIDS & Co-Infections Conference (APACC), held virtually in October 2020. APACC is a regional-level HIV research conference that provides

opportunities for local clinicians, students, and researchers to submit abstracts for presentation.

The 2019 TREAT Asia Annual Network Meeting was held in October 2019 in Bangkok, Thailand, where adult and pediatric investigators, donors, and program partners gathered to review progress on the network's research agenda, hear about regional HIV-related policy priorities, and plan for future initiatives.

THE GMT INITIATIVE ▼

The two implementation science studies being supported by amfAR's GMT Initiative came to an end in 2019, bringing the initiative to a close. The three-year projects, in Myanmar and Thailand, were aimed at determining the most effective ways of engaging gay men, other men who have sex with men (MSM), and transgender individuals (collectively, GMT) at risk of infection or already living with HIV. The goal was to help those who were HIV-negative stay uninfected, and help HIV-positive individuals to begin and remain on treatment. A third project, in Peru, ended in 2018.

PUBLIC INFORMATION ▼


amfAR disseminates information on important HIV-related research, treatment, prevention, and policy issues for diverse audiences to increase awareness and knowledge of the pandemic. amfAR publishes a wide range of educational materials, maintains an informative website, and engages respected public figures, HIV/AIDS scientists, and policymakers in communicating the need for continued research to develop new methods of prevention, treatment, and, ultimately, a cure for HIV.

The COVID-19 Pandemic

When the COVID-19 crisis emerged in early 2020, amfAR dedicated a section of its website to information on the coronavirus and the intersection of HIV and COVID-19 in particular. The section featured resources for people living with HIV and news of the latest studies as more and more data emerged. Audiovisual content included a video announcement of the launch of the amfAR Fund to Fight COVID-19 and a series of interviews featuring amfAR VP and Director of Research Dr. Rowena Johnston and amfAR grantees who had quickly pivoted to research on COVID-19. These informative interviews covered topics such as testing, vaccine development, experimental treatments, and COVID in children, and garnered tens of thousands of views.

Educational Materials

amfAR's newsletter *Innovations* is published twice a year and distributed to more than 40,000 people, while a monthly email newsletter reaches approximately 10,000 readers.



As the COVID-19 pandemic evolved, amfAR explored emerging research priorities through a series of video interviews with leading scientists.

The Foundation’s websites—www.amfar.org and www.curecountdown.org—feature news, interviews, and original articles covering HIV research, policy, the global epidemic, and amfAR programs and activities. The websites attract a combined average of 46,000 visitors per month. amfAR also creates and distributes reports, press releases, and updates on major HIV/AIDS issues and conducts public service advertising campaigns that have been instrumental in educating policymakers, healthcare professionals, people living with HIV/AIDS, and the public.

amfAR’s Public Information team also works closely with the Public Policy Office (see above) to produce a wide range of issue briefs, facts sheets, infographics, and reports.

Epic Voices

amfAR’s Epic Voices, an online video series that aims to reenergize the response to HIV among millennial and LGBTQ communities, continued to generate significant engagement in 2020. A ten-episode Instagram IGTV series featuring the videos received more than 7,500 views. The series profiles HIV activists across the country who share their unique journeys, their insights on living with HIV, and the bold steps they have taken in the fight against the epidemic.

Social Media

amfAR has vigorously expanded its presence in the social media arena, reaching large numbers of people, including a younger demographic that is often less educated about HIV and the AIDS epidemic. The Foundation regularly adds educational and fundraising news and information to its Facebook page and Twitter and Instagram feeds. amfAR has over 76,000 likes on Facebook, more than 43,000 Twitter followers, and 159,000 Instagram followers.

Media Outreach

In FY2020, amfAR continued to work closely with the media to raise the profile of HIV/AIDS, both domestically and internationally, and to help ensure the accuracy of HIV-related press coverage. Articles and reports involving amfAR—many of which included interviews with staff—were carried in numerous media outlets, including *The New York Times*, *The Wall Street Journal*, *The Washington Post*, *Fast Company*, *The Atlantic*, *Vice*, *HuffPost*, *Business Insider*, *U.S. News & World Report*, *Vox*, *Vanity Fair*, *New York Magazine*, *People*, *Gizmodo*, *The Verge*, *The Advocate*, *Politico*, *The Hill*, Reuters, Associated Press, CBS News, BBC News, CNN, NPR, MSNBC, ABC News, and NBC News.

Celebrity Support

amfAR’s public awareness efforts are greatly enhanced by the committed support of public figures who lend their voices and donate their time, talents, and resources to help sustain the Foundation’s mission. Support of amfAR by prominent public figures began with the late Dame Elizabeth Taylor, amfAR’s Founding International Chairman, and others have followed in her footsteps.

amfAR is profoundly grateful for the continuing support of celebrities from all over the world, including Iman, James Corden, Tom Ford, Cheyenne Jackson, Paris Jackson, Heidi Klum, Katy Perry, Julia Roberts, Alan Cumming, Christina Aguilera, Gwyneth Paltrow, Lily Aldridge, Adrien Brody, Andy Cohen, Diplo, Padma Lakshmi, Billy Porter, Zac Posen, Laid Ribeiro, Coco Rocha, Carine Roitfeld, Amber Valletta, Virgil Abloh, Alessandra Ambrosio,

Peter Dundas, Ashley Graham, Winnie Harlow, Miranda Kerr, Karlie Kloss, Karolina Kurkova, Adriana Lima, Jasmine Sanders, Shanina Shaik, Irina Shayk, Joan Smalls, Lara Stone, Jasmine Tookes, and Diane von Fürstenberg.



amfAR honored legendary model and entrepreneur Iman at the 2020 New York Gala for her contributions to the fight against AIDS.

GRANTS / FELLOWSHIPS / AWARDS

2020 RESEARCH GRANTS, FELLOWSHIPS

All projects below were awarded funding during the period October 1, 2019 through September 30, 2020.

¹Supported with funds provided by the FAIR Foundation

amfAR FUND TO FIGHT COVID-19

[Predictors of SARS-CoV-2 antibody responses after severe COVID](#)

Daniel Kaufmann, MD
Université de Montréal, Centre de Recherche du CHUM
Montreal, Canada
\$209,712

[Protecting epithelial cell organ from COVID-19 attack](#)

Matthias Kretzler, MD, PhD
The University of Michigan
Ann Arbor, MI
\$155,650

amfAR RESEARCH CONSORTIUM ON HIV ERADICATION (ARCHE): GENE THERAPY

[Preclinical in vivo non-human primate study of combined treatment strategies](#)

Hildegard Büning, PhD
Hannover Medical School
Hannover, Germany
\$1,558,021

IMPACT GRANTS: GAINING INSIGHTS FROM THE CLINIC

[Identification of integrative multi-omics signature predictive of HIV replication control without the use of ART](#)

Simone Gonçalves da Fonseca, PhD
Fundação de Apoio à Pesquisa (FUNAPE)
Goiânia, Brazil
\$63,040¹

[Deep learning methods to personalize antibody therapeutics for delaying viral rebound after cessation of ART](#)

Hillel Haim, MD, PhD
University of Iowa
Iowa City, IA
\$149,995

[The driving force of the clonally expanding HIV-1-infected cells - a single-cell approach](#)

Ya-Chi Ho, MD, PhD
Yale University
New Haven, CT
\$150,000

[Integrating Transcriptomic and Proviral Integration Site Data-Sets to Define Mechanisms of 'CTL Resistance' in Reservoir](#)

Brad Jones, PhD
Weill Medical College of Cornell University
New York, NY
\$150,000

[A hidden reservoir? An in-depth analysis of HIV integration across the entire human genome](#)

Sharon Lewin, FRACP, PhD
University of Melbourne
Melbourne, Australia
\$149,999

SYNERGY GRANT: GAINING INSIGHTS FROM THE CLINIC

[Humoral Immune Response in HIV Rebound](#)

Jonathan Li, MD, MMSc
The Brigham and Women's Hospital, Inc.
Boston, MA
\$50,000

MATHILDE KRIM FELLOWSHIPS IN BIOMEDICAL RESEARCH

[Harnessing Universal MHC-E-Restricted T cell Receptors for HIV Cure](#)

Shaheed Abdulhaqq, PhD
Oregon Health and Science University
Portland, OR
\$150,000

[HIV-1 fusion studied by parallel single molecule FRET and cryo-electron tomography](#)

Maolin Lu, PhD
Yale University
New Haven, CT
\$150,000



2020 TREAT ASIA GRANTS AND AWARDS

All projects listed below were awarded funding for the period October 1, 2019, through September 30, 2020.

¹Supported by National Institutes of Health federal award number U01AI069907, with funds from the National Institute of Allergy and Infectious Diseases, the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development, the National Cancer Institute, the National Institute of Mental Health, the National Institute on Drug Abuse, the National Heart, Lung, and Blood Institute, the National Institute on Alcohol Abuse and Alcoholism, the National Institute of Diabetes and Digestive and Kidney Diseases, and the Fogarty International Center

²Supported by National Institutes of Health federal award number D43TW011302, funded by the Fogarty International Center and the National Institute of Mental Health

³Supported with funds provided by Life Ball.

AUSTRALIA

University of New South Wales

Sydney
Matthew G. Law, PhD
IeDEA Asia-Pacific Research Collaboration: Data Management and Analysis Center
\$552,520¹

AUSTRALIAN HIV OBSERVATIONAL DATABASE (AHOD) SITES

O'Brien Street Practice

Adelaide
William Donohue, MBBS
\$1,275

Sunshine Coast Hospital and Health Service

Birtinya
David Sowden, MBBS
\$7,500¹

Sexual Health and HIV Service In Metro North

Brisbane
Diane Rowling, MBBS, MTH, F(PHM), RACP, FACSHM
\$7,500¹

Cairns Sexual Health Service

Cairns North
Darren Russell, MD
\$7,500¹

RPA Sexual Health Clinic

Camperdown
David Templeton, PhD
\$7,425¹

Melbourne Sexual Health Centre

Carlton
Richard Teague, MBBS (Monash Uni), FRACGP, FRChSHM
\$5,475¹

Monash Health - Clayton

Clayton
Ian Woolley, MBBS, FRACP
\$7,500¹

D.A. Ellis Pty., Ltd.

Coffs Harbour
David Ellis, MBBS
\$450

Northern Territory of Australia Dept of Health through Top End Health Service

Darwin
Manoji Gunathilake, MBBS, MD, FChSHM
\$2,100

Nepean Blue Mountains Local Health District, Blue Mountains Sexual Health and HIV Clinic

Katoomba
Eva Jackson, MBBS, FChSHM
\$1,950

Nepean Blue Mountains Local Health District, Nepean Sexual Health Clinic

Kingswood
Eva Jackson, MBBS, FChSHM
\$1,950

Sexual Health and AIDS Services (SHAIDS)

Lismore
David Smith, MBBS, DipVen, FChSHM, GrapDip BA
\$7,500¹

Victorian HIV Service, Infectious Diseases Department, The Alfred Hospital

Melbourne
Jennifer Hoy, MBBS
\$7,500¹

Northside Clinic (Vic) Pty Ltd

North Fitzroy
Richard Moore, MBBS
\$7,500¹

Prahran Market Clinic Pty Ltd

Prahran
Norman Roth, MBBS, FChSHM
\$7,350¹

East Sydney Doctors

Sydney
David Baker, MB, ChB, Dip Med (Sexual Health), DCH
\$7,500¹

Holdsworth House Medical Practice

Sydney
Mark Bloch, MD
\$7,500¹

St. Vincent's Hospital Sydney Limited

Sydney
Andrew Carr, MD
\$7,500¹

Sydney Sexual Health Centre, Sydney Hospital

Sydney
Rick Varma, MBBS, MRCP
\$6,300¹

Taylor Square Private Clinic

Sydney
Robert Finlayson, MBBS, (Syd) Di FChSHM, DipVen, MB BS
\$6,525¹

Clinic 468, HNE Sexual Health, Hunter New England Local Health District

Tamworth NEMSC
Nathan Ryder, MD
\$1,650

Illawarra Shoalhaven Local Health District

Warrawong
Katherine Brown, MD
\$1,725

CAMBODIA

National Center for HIV/AIDS, Dermatology & STDS / Cambodia National Institute of Public Health

Phnom Penh
Ly Penh Sun, MD, MSc
TAHOD Low Intensity Transfer (TAHOD-LITE)
\$9,500¹

TREAT Asia HIV Observational Database (TAHOD)
\$20,800¹

TREAT Asia Pediatric HIV Observational Database (TApHOD) Site
\$25,000¹

CHINA

Queen Elizabeth Hospital

Hong Kong
Man Po Lee, MBBS
TAHOD Low Intensity Transfer (TAHOD LITE)
\$7,500¹

TREAT Asia HIV Observational Database (TAHOD) including NCD Data
\$22,800¹

INDIA

The Voluntary Health Services

Chennai
Naglingeswaran Kumarasamy, MD, MBBS, PhD
TAHOD Low Intensity Transfer (TAHOD-LITE)
\$15,000 (funding awarded in 2020 for project years 14 & 15)

TREAT Asia HIV Observational Database (TAHOD) including NCD Data
\$22,800¹

TREAT Asia Pediatric HIV Observational Database (TApHOD)
\$7,500¹

BJ Medical College & Sassoon General Hospitals
Pune
Aarti Kinikar, MD, DCH, DNB, MRCP-Pediatrics UK
TREAT Asia Pediatric HIV Observational Database (TApHOD)
\$7,500¹

Shashikala Sangle, MD
IeDEA Sentinel Research Network (SRN)—Asia-Pacific
\$113,765¹

TREAT Asia HIV Observational Database (TAHOD) including NCD Data
\$21,085¹

Institute of Infectious Diseases
Pune
Sanjay Pujari, MD, AAHIVS, MBBS
TAHOD Low Intensity Transfer (TAHOD-LITE)
\$9,500

TREAT Asia HIV Observational Database (TAHOD) including NCD Data
\$22,300¹

INDONESIA

Sanglah Hospital, Udayana University School of Medicine
Denpasar
Tuti Parwati Merati, MD
TAHOD Low Intensity Transfer (TAHOD-LITE)
\$8,000¹

TREAT Asia HIV Observational Database (TAHOD) including NCD Data
\$22,800¹

Ketut Dewi Kumara Wati, MD
TREAT Asia Pediatric HIV Observational Database (TApHOD)
\$7,500¹

Cipto Mangunkusumo General Hospital
Jakarta
Nia Kurniati, MD
TREAT Asia Pediatric HIV Observational Database (TApHOD)
\$7,500¹

Evy Yuniastuti, MD, PhD
TREAT Asia HIV Observational Database (TAHOD) including NCD Data
\$23,000¹

JAPAN

National Center for Global Health and Medicine
Tokyo
Junko Tanuma, MD, PhD
TREAT Asia HIV Observational Database (TAHOD)
\$16,640¹

MALAYSIA

Penang Hospital
Georgetown
Revathy Nallusamy, MBBS
TREAT Asia Pediatric HIV Observational Database (TApHOD)
\$5,3763 (funding awarded in 2020 for project years 14 & 15)

Hospital Raja Perempuan Zainab II
Kota Bharu
Nik Khairulddin Nik Yusoff, MD
TREAT Asia Pediatric HIV Observational Database (TApHOD)
\$7,500¹

Hospital Likas
Kota Kinabalu
Fong Siew Moy, MBBS
TREAT Asia Pediatric HIV Observational Database (TApHOD)
\$7,500¹

Pediatric Institute, Hospital Kuala Lumpur
Kuala Lumpur
Thahira Mohamed, MBBS
TREAT Asia Pediatric HIV Observational Database (TApHOD)
\$7,500¹

University of Malaya
Kuala Lumpur
Reena Rajasuriar, PhD
Capacity development for HIV and mental health research in Asia (CHIMERA)
\$6,048

University of Malaya Medical Center
Kuala Lumpur
Raja Iskandar Shah Raja Azwa, MBBS
Substance use, Stigma, Depression and Disability among Adults with HIV in Asia (S2D2)
\$2,514¹

TREAT Asia HIV Observational Database (TAHOD) including NCD Data
\$22,300¹

Sungai Buloh Hospital
Sungai Buloh
Yasmin Mohamed Gani, MD
TREAT Asia HIV Observational Database (TAHOD) including NCD Data
\$21,260¹

PHILIPPINES

Asian Foundation for Tropical Medicine, Inc.
Muntinlupa City
Rossana Ditangco, MD
Substance use, Stigma, Depression and Disability among Adults with HIV in Asia (S2D2)
\$6,500

Research Institute for Tropical Medicine
Muntinlupa City
Rossana Ditangco, MD
Adolescent and Young Adult network of IeDEA (AYANI) Study Site
\$12,718¹

TREAT Asia HIV Observational Database (TAHOD) including NCD Data
\$22,300¹

SINGAPORE

Tan Tock Seng Hospital
Singapore
Oon Tek Ng, MBBS, MRCP, MMed, MPH
TREAT Asia HIV Observational Database (TAHOD)
\$18,200¹

SOUTH KOREA

Yonsei University College of Medicine
Seoul
Jun Yong Choi, MD, PhD
TAHOD Low Intensity Transfer (TAHOD-LITE)
\$6,000¹

TREAT Asia HIV Observational Database (TAHOD) including NCD Data
\$17,640¹

TAIWAN

Taipei Veterans General Hospital
Taipei City
Yu-Jiun Chan, MD
TREAT Asia HIV Observational Database (TAHOD) including NCD Data
\$24,800¹

THAILAND

Chulalongkorn University
Bangkok
Suvarporn Anugulruengkitt, MD
Study on Pregnancy and Birth Outcomes among Youth living with HIV in Asia
\$1,500¹

Thanyawee Puthanakit, MD
Adolescent and Young Adult network of IeDEA (AYANI) Study Site
\$17,146¹

TREAT Asia Pediatric HIV Observational Database (TApHOD)
\$15,000¹

HIV-NAT / Thai Red Cross AIDS Research Centre
Bangkok
Anchalee Avihingsanon, MD, PhD
Substance use, Stigma, Depression and Disability among Adults with HIV in Asia (S2D2)
\$2,514¹

TAHOD Low Intensity Transfer (TAHOD-LITE)
\$8,000¹

TREAT Asia HIV Observational Database (TAHOD) including NCD Data
\$24,300¹

Institute of HIV Research and Innovation (IHRI)
Bangkok
Nittaya Phanuphak-Pungpapong, MD, PhD
Amphetamine-type stimulant use, HIV incidence, and ART adherence among Thai MSM and transgender women
\$76,902¹

Anal HPV and risk for anal high-grade squamous intraepithelial lesion among Thai MSM with acute HIV infection
\$78,268¹

Mahidol University by Faculty of Medicine Siriraj Hospital
Bangkok
Kulkanya Chokephaibulkit, MD
TREAT Asia Pediatric HIV Observational Database (TApHOD)
\$7,500¹

Ramathibodi Hospital, Mahidol University
Bangkok
Sasisopin Kiertiburanakul, MD, MHS
TAHOD Low Intensity Transfer (TAHOD-LITE)
\$10,000¹

ហេតុអ្វីចាំបាច់ត្រូវផ្ទេរពីគ្លីនិក HIV កុមារ ទៅគ្លីនិក HIV មនុស្សចាស់?



TREAT Asia HIV Observational Database (TAHOD) including NCD Data
\$22,800¹

Chiang Mai University - Research Institute for Health Sciences

Chiang Mai
Romane Chaiwarith, MD, MHS
TREAT Asia HIV Observational Database (TAHOD) including NCD Data
\$23,800¹

Tavitiya Sudjaritruk, MD, ScM
Adolescent and Young Adult network of leDEA (AYANI) Study Site
\$17,182¹

Study on Pregnancy and Birth Outcomes among Youth living with HIV in Asia
\$1,828¹

TREAT Asia Pediatric HIV Observational Database (TApHOD)
\$15,000¹

Chiangrai Prachanukroh Hospital

Chiang Rai
Suwimon Khusuwan, MD
TAHOD Low Intensity Transfer (TAHOD-LITE)
\$9,500¹

TREAT Asia HIV Observational Database (TAHOD) including NCD Data
\$23,300¹

Pradthana Ounchanum, MD
Study on Pregnancy and Birth Outcomes among Youth living with HIV in Asia
\$5,492¹

TREAT Asia Pediatric HIV Observational Database (TApHOD)
\$7,500¹

Srinagarind Hospital, Khon Kaen University

Khon Kaen
Pagakrong Lumbiganon, MD
Study on Pregnancy and Birth Outcomes among Youth living with HIV in Asia
\$1,394¹

TREAT Asia Pediatric HIV Observational Database (TApHOD)
\$7,500¹

Purple Haze Company Limited

Bangkok
Tarandeep Anand
The impact of online interventions on the HIV prevention/treatment cascade among MSM and TG Individuals
\$30,000¹

Little Birds Foundation

Bangkok
Usanee Janngoon
Quality of life development for adolescents and youth living with HIV
\$10,000³

USA

Johns Hopkins University

Baltimore, MD
Vidya Mave, MD, MPH & Amita Gupta, MD, MHA
A study to evaluate the markers of lung impairment in HIV-TB coinfecting Indian adults
\$20,791¹

Epidemiology of HIV/AIDS and associated comorbidities in a public antiretroviral treatment (ART) clinic in Pune, India
\$411,571¹ (funding awarded in 2020 for project years 14 & 15)

leDEA Sentinel Research Network (SRN)—Asia-Pacific
\$23,571¹

New Hope for Cambodian Children

Killeen, TX
John Tucker
HIV Education: New Hope for Cambodian Children
\$20,024³

Columbia University

New York, NY
Milton Wainberg, MD
Capacity development for HIV and mental health research in Asia (CHIMERA)
\$46,250²

VIETNAM

Bach Mai Hospital

Hanoi
Do Duy Cuong, MD, PhD
TAHOD Low Intensity Transfer (TAHOD-LITE)
\$8,000¹

TREAT Asia HIV Observational Database (TAHOD) including NCD Data
\$22,300¹

National Hospital of Pediatrics

Hanoi
Nguyen Van Lam, MD, MSc
Study on Pregnancy and Birth Outcomes among Youth living with HIV in Asia
\$1,230¹

TREAT Asia Pediatric HIV Observational Database (TApHOD)
\$20,000¹

National Hospital of Tropical Diseases

Hanoi
Pham Ngoc Thach, MD, PhD
TAHOD Low Intensity Transfer (TAHOD-LITE)
\$8,000¹

TREAT Asia HIV Observational Database (TAHOD) including NCD Data
\$22,300¹

Children's Hospital 1


Ho Chi Minh City
Truong Huu Khanh, MD
TREAT Asia Pediatric HIV Observational Database (TApHOD)
\$20,000¹

Children's Hospital 2

Ho Chi Minh City
Do Chau Viet, MD
Study on Pregnancy and Birth Outcomes among Youth living with HIV in Asia
\$1,442¹


TREAT Asia Pediatric HIV Observational Database (TApHOD)
\$20,000¹

FINANCIALS



EXPENSES

| | | |
|------------------------|-----------|-------------------|
| Program | \$ | 21,741,025 |
| Fundraising | | 4,533,696 |
| Management and general | | 2,357,534 |
| Total | \$ | 28,632,255 |



PROGRAM EXPENSES

| | | |
|--------------------|-----------|-------------------|
| Research | \$ | 11,753,894 |
| TREAT Asia | | 4,546,418 |
| GMT Initiative | | 0 |
| Public Policy | | 1,776,060 |
| Public Information | | 3,664,653 |
| Total | \$ | 21,741,025 |

FINANCIAL HIGHLIGHTS

For the year ended September 30, 2020

| | | |
|---|-----------|-------------------|
| Public Support and Revenue | | |
| Public support | \$ | 2,700,163 |
| Special events | | 5,760,796 |
| Planned giving | | 3,066,238 |
| Government funding | | 6,657,827 |
| Investment income and other revenue | | 2,608,564 |
| Total public support and revenue | \$ | 20,793,588 |
| <hr/> | | |
| Expenses | | |
| Research | \$ | 11,753,894 |
| TREAT Asia | | 4,546,418 |
| GMT Initiative | | 0 |
| Public Policy | | 1,776,060 |
| Public Information | | 3,664,653 |
| Total program services | \$ | 21,741,025 |
| <hr/> | | |
| Fundraising | | 4,533,696 |
| Management and general | | 2,357,534 |
| Total supporting services | \$ | 6,891,230 |
| <hr/> | | |
| Total expenses | \$ | 28,632,255 |
| <hr/> | | |
| Change in net assets | | (7,838,667) |
| Net assets, beginning of year | | 49,484,561 |
| Net assets, end of year | \$ | 41,645,894 |

STATEMENT OF FINANCIAL POSITION

| | | |
|---|-----------|-------------------|
| Assets | | |
| Cash and investments | \$ | 44,474,143 |
| Pledges and receivables, net | | 4,479,604 |
| Prepaid expenses and other assets | | 2,859,940 |
| Furniture, equipment, and leasehold improvements, net | | 2,925,831 |
| Total Assets | \$ | 54,739,518 |
| <hr/> | | |
| Liabilities | | |
| Accounts payable and accrued expenses | \$ | 2,489,524 |
| CARES Act Paycheck Protection Program loan | | 1,643,364 |
| Grants and fellowships payable, net | | 1,052,816 |
| Deferred support and refundable advances | | 6,138,184 |
| Other long-term liabilities | | 1,769,736 |
| Total liabilities | \$ | 13,093,624 |
| <hr/> | | |
| Total net assets | \$ | 41,645,894 |
| <hr/> | | |
| Total liabilities and net assets | \$ | 54,739,518 |

BOARD OF TRUSTEES

Fiscal year 2020

Chairman of the Board*

[William H. Roedy](#)

Chairman, MTV International (retired)
London

United Kingdom

*(10/01/2019-06/26/2020)

Vice Chair*

[Cindy Rachofsky](#)

Philanthropist
Dallas, Texas

*(10/01/2019-06/26/2020)

Co-Chair*

[T. Ryan Greenawalt](#)

Managing Director
Ramirez & Co.

Los Angeles, CA

*(07/01/2020-present)

Co-Chair*

[Kevin McClatchy](#)

Chairman of the Board
The McClatchy Company
West Palm Beach, FL

*(07/01/2020-present)

Treasurer

[Raymond F. Schinazi, PhD, DSc](#)

Frances Winship Walters Professor
Emory University School of Medicine
Atlanta, GA

Secretary*

[Arlen H. Andelson](#)

Senior Partner (retired)
Andelson & Andelson

Los Angeles, CA

*(deceased 10/26/2019)

Secretary*

[Jay Ellis](#)

Jay Ellis Foundation
Los Angeles, CA

*(12/19/2019)

TRUSTEES

[Danielle Alexandra](#)

CEO, London Film and Television Group
Business Ambassador, Film, Television and Global
Digital New Media
Los Angeles, CA

[David Bohnett](#)

Chairman
David Bohnett Foundation
Beverly Hills, CA

[Donald Dye](#)

Chairman, Sky Lake Partners
New York, NY

[Aileen Getty](#)

The Aileen Getty Foundation
Reno, NV

[Glenn Isaacson](#)

Vice Chairman
Global Brokerage
Cushman & Wakefield
New York, NY

[Michael Lorber](#)

Senior Vice President
Douglas Elliman Real Estate
New York, NY

[Edward Milstein](#)

Co-Chairman
Milstein Brothers Capital Partners
New York, NY

[Jeffrey Schoenfeld](#)

Partner
Head of Global Institutional Business Development
& Relationship Management
Brown Brothers Harriman
New York, NY

[Alan Schwartz](#)

Executive Chairman
Guggenheim Partners, LLC
New York, NY

[Mario Stevenson, Ph.D.](#)

Professor of Medicine
Chief, Division of Infectious Diseases
Leonard M. Miller School of Medicine
University of Miami
Miami, FL

[Phill Wilson](#)

Founder and CEO, Black AIDS Institute (retired)
Los Angeles, CA

TRUSTEE EMERITUS

[Arthur J. Ammann, M.D.](#)

President, Global Strategies for HIV Prevention
Clinical Professor of Pediatrics
University of California, San Francisco
San Francisco, CA

IN MEMORIAM

[Mathilde Krim, Ph.D.](#)

Founding Chairman

[Dame Elizabeth Taylor](#)

Founding International Chairman

[Arlen H. Andelson](#)

[Sheldon W. Andelson, Esq.](#)

[Arnold W. Klein, M.D.](#)

[Mrs. Albert D. Lasker](#)

[Jonathan M. Mann, M.D., M.P.H.](#)

[Maxine Mesinger](#)

[Pauline Phillips](#)

[Natasha Richardson](#)

[Allan Rosenfield, M.D.](#)

[Peter Scott, Esq.](#)

[Wallace Sheft, C.P.A.](#)

[Tom Stoddard](#)

[Joel D. Weisman, D.O.](#)

SPECIAL APPOINTMENT

Global Fundraising Chairman

[Milutin Gatsby](#)

SCIENTIFIC ADVISORY COMMITTEE

*Adjunct Member

[Mohamed Abdel-Mohsen, Ph.D.*](#)

Assistant Professor
Vaccine & Immunotherapy Center
The Wistar Institute

[Maria Luisa Alcaide, M.D.*](#)

Associate Professor of Clinical Infectious Diseases
Miller School of Medicine
University of Miami

[Richard Ambinder, M.D., Ph.D.*](#)

Director, Division of Hematologic Malignancies
Professor of Oncology
School of Medicine
Johns Hopkins University

[Jintanat Ananworanich, M.D., Ph.D.](#)

Associate Director for Therapeutics Research
US Military HIV Research Program

[Patrick Arbutnot*](#)

Professor
Director, Wits/SAMRC Antiviral Gene Therapy
Research Unit
Faculty of Health Sciences
University of the Witwatersrand

[Robert Arduino, M.D.*](#)

Professor
Department of Medicine-Infectious Diseases
University of Texas Health Science Center at
Houston

[Judith Auerbach, Ph.D.*](#)

Professor of Medicine
School of Medicine
University of California, San Francisco

[Andrew Badley, M.D.*](#)

Professor of Medicine
Mayo Clinic College of Medicine

[Ben Berkhout, Ph.D.*](#)

Professor
Department of Medical Microbiology
Academic Medical Center of the University of
Amsterdam

[Pascal Bessong, Ph.D.*](#)

Professor of Microbiology and Global Health
Chair of the HIV/AIDS & Global Health Research
Programme
University of Venda

[Daniel Blanco-Melo, Ph.D.*](#)

Department of Microbiology
Icahn School of Medicine at Mount Sinai

[Eli Bortiz, M.D., Ph.D.*](#)

Chief, Virus Persistence and Dynamics Section
(VPDS)
National Institute of Allergy and Infectious
Diseases
National Institutes of Health

[Alberto Bosque, Ph.D.*](#)

Assistant Professor
Department of Microbiology, Immunology, and
Tropical Medicine
The George Washington University

Jason Brenchley, Ph.D.*

Senior Investigator
Immunopathogenesis Section
National Institute of Allergy and Infectious Diseases
National Institutes of Health

Zabrina Brumme, Ph.D.*

Professor, CIHR New Investigator, MSFHR Scholar
Faculty of Health Sciences
Simon Fraser University

Dennis R. Burton, Ph.D.

Professor
Department of Immunology
The Scripps Research Institute

Salvatore T. Butera, D.V.M., Ph.D.

Chief Science Officer
Scripps CHAVI-ID
The Scripps Research Institute

Cheryl Cameron, Ph.D.*

Assistant Professor
Case Western Reserve University

Edward Campbell, Ph.D.

Assistant Professor
Department of Microbiology and Immunology
School of Medicine
Loyola University at Chicago

Alex Carballo-Diequez, Ph.D.

Co-Director and Senior Research Scientist
HIV Center for Clinical and Behavioral Studies
New York State Psychiatric Institute
Columbia University

Ann Chahroudi, M.D., Ph.D.*

Associate Director, Clinical Affairs
Medical Scientist Training Program
Associate Professor, Infectious Disease
Department of Pediatrics
School of Medicine
Emory University

Nicolas Chomont, Ph.D.*

Associate Research Professor
Department of Microbiology and Immunology
Université de Montréal, Centre de Recherche du CHUM

Amy Chung, Ph.D.*

Laboratory Head
University of Melbourne

David B. Clifford, M.D.

Professor
Department of Neurology
Washington University School of Medicine

C. Budd Colby, Ph.D.

Principal
Colby Biomedical Ventures

Grant Colfax, M.D.

Director
Marin Health and Human Services
San Rafael, California

Deborah Jean Cotton, M.D., M.P.H.

Professor of Medicine
Boston University School of Medicine

Bryan R. Cullen, Ph.D., D.Sc.

James B. Duke Professor
Department of Molecular Genetics and Microbiology
Director, Duke University Center for Virology
Duke University Medical Center

Susanna Cunningham-Rundles, Ph.D.

Professor Emerita of Research Immunology
Department of Pediatrics
Weill Cornell Medical College

Richard Thomas D'Aquila, M.D.

The Howard Taylor Ricketts Professor of Medicine
Division of Infectious Diseases
Director, Northwestern HIV Translational Research Center
Feinberg School of Medicine
Northwestern University

Miles Davenport, D.Phil.*

Professor
Centre for Vascular Research
University of New South Wales

Zeger Debyser, M.D., Ph.D.*

Professor
Department of Molecular Medicine
Katholieke Universiteit Leuven

Steven Deeks, M.D.*

Professor
School of Medicine
University of California, San Francisco

Bruno De Geest, Ph.D.

Chemical Engineer
Laboratory of Pharmaceutical Technology
Ghent University Hospital

Sherry Deren, Ph.D.

Co-Director
Center for Drug Use and HIV Research
New York University College of Nursing

Roger Detels, M.D., M.S.

Professor of Epidemiology
School of Public Health
University of California, Los Angeles

Carl W. Dieffenbach, Ph.D.

Director
Division of AIDS (DAIDS)
National Institute of Allergy and Infectious Diseases
National Institutes of Health

Dario Dileria, Ph.D.*

Research Assistant Professor
Pathology / Yerkes National Primate Research Center at Emory Vaccine Center
Emory University

Ivan D'Orso, Ph.D.*

Associate Professor
Department of Microbiology
University of Texas Southwestern

Daniel C. Douek, M.D., Ph.D.

Chief, Human Immunology Section
Vaccine Research Center
National Institute of Allergy and Infectious Diseases
National Institutes of Health

D. Peter Drotman, M.D., M.P.H.

Editor-in-Chief
Emerging Infectious Diseases
Centers for Disease Control and Prevention

Anke A. Ehrhardt, Ph.D.

Director
Division of Gender, Sexuality, & Health
Program for the Study of LGBT Health
NYS Psychiatric Institute/Columbia University

Homayoon Farzadegan, Ph.D.

Professor
Department of Epidemiology
Johns Hopkins Bloomberg School of Public Health

Maurizio Federico, Ph.D.*

Director
National AIDS Center, Division of Pathogenesis of Retroviruses
Istituto Superiore di Sanità

Daniel Fera, Ph.D.*

Assistant Professor
Department of Biochemistry
Swarthmore College

Dianne M. Finkelstein, Ph.D.

Professor of Biostatistics
Harvard School of Public Health
Director, Cancer Center Biostatistics
Massachusetts General Hospital

Andrés Finzi, Ph.D.*

Associate Professor
Department of Microbiology and Immunology
Université de Montréal, Centre de Recherche du CHUM

Gerald Herbert Friedland, M.D.

Professor and Director
AIDS Care Program
Department of Internal Medicine
Yale School of Medicine

Christina Gavegnano, Ph.D.*

Assistant Professor
Laboratory of Biochemical Pharmacology
Department of Pediatrics
Emory University

Howard E. Gendelman, M.D.

Professor and Chair, Department of Pharmacology and Experimental Neuroscience
Margaret R. Larson Professor of Internal Medicine and Infectious Diseases
Director, Center for Neurodegenerative Disorders
University of Nebraska Medical Center

Sara Gianella Weibel, M.D.*

Assistant Professor of Medicine
CFAR - Center for AIDS Research
Department of Medicine, Division of Infectious Diseases
University of California, San Diego

Nancy L. Haigwood, Ph.D.

Director and Senior Scientist
Division of Pathobiology and Immunology
Oregon National Primate Research Center
Oregon Health and Science University

Andrew Henderson, Ph.D.*

Associate Professor
School of Medicine
Boston University

Alon Herschhorn, Ph.D.*

Assistant Professor of Medicine
Division of Infectious Diseases and International Medicine
University of Minnesota

Charles H. Hinkin, Ph.D.

Professor
Department of Psychiatry and Biobehavioral Sciences
David Geffen School of Medicine
University of California, Los Angeles

David Ho, M.D.

Scientific Director, Chief Executive Officer
Aaron Diamond AIDS Research Center

Ya-Chi Ho, M.D., Ph.D.*

Assistant Professor of Microbial Pathogenesis
and Medicine
Microbial Pathogenesis
Yale University

Eric Hunter, Ph.D.*

Professor
Emory Vaccine Center
Department of Pathology and Laboratory Medicine
School of Medicine
Emory University

Thomas J. Hope, Ph.D.

Professor
Department of Cell and Molecular Biology
Feinberg School of Medicine
Northwestern University

Shiu-Lok Hu, Ph.D.

Professor
School of Pharmacy
University of Washington

Nuria Izquierdo-Useros, Ph.D.*

Associate Researcher
AIDS Research Institute IrsiCaixa

Moses Joloba, MBChB, MS, Ph.D.*

Associate Professor
College of Health Sciences, Department of
Medical Microbiology
Makerere University
School of Medicine
Case Western Reserve University

R. Brad Jones, Ph.D.*

Assistant Professor of Immunology in Medicine
Graduate School of Medical Sciences
Weill Medical College of Cornell University

Edward Kankaka, MBChB, MPH*

Rakai Health Sciences Program

Jonathan Karn, Ph.D.*

Director
Center for AIDS Research
Case Western Reserve University

Vineet KewalRamani, Ph.D.

Chief, Model Development Section
HIV Drug Resistance Program
National Cancer Institute
National Institutes of Health

Scott Kitchen, Ph.D.

Assistant Professor of Medicine
Division of Hematology and Oncology
David Geffen School of Medicine
University of California, Los Angeles

Richard Kornbluth, M.D., Ph.D.

President and Chief Scientific Officer
Multimeric Biotherapeutics, Inc.

Richard A. Koup, M.D.

Deputy Director, Vaccine Research Center
Chief, Immunology Laboratory
National Institute of Allergy and Infectious
Diseases
National Institutes of Health

Nathaniel R. Landau, Ph.D.

Professor
Department of Microbiology
New York University School of Medicine

Alan L. Landay, Ph.D.

Professor and Chairman
Department of Immunology and Microbiology
Rush-Presbyterian-St. Luke's Medical Center

Michael Lederman, M.D.

Scott R. Inkle Professor of Medicine
Associate Director, Center for AIDS Research
Case Western Reserve University

Tun-Hou Lee, D.Sc.

Professor of Virology, Emeritus
Department of Immunology and Infectious
Diseases
Harvard School of Public Health

Michael J. Leibowitz, M.D., Ph.D.

Professor, Medical Microbiology and Immunology
University of California, Davis

Robert J. Levine, M.D.

Professor of Medicine
Center for Interdisciplinary Research on AIDS
Yale University

Judy Lieberman, M.D., Ph.D.

Senior Investigator
Immune Disease Institute
Professor of Pediatrics
Harvard Medical School

Manuel Llano, M.D., Ph.D.*

Assistant Professor
University of Texas at El Paso

Jeremy Luban, Ph.D.*

David J. Freeland Chair in AIDS Research
Professor, Program in Molecular Medicine and
Biochemistry & Molecular Pharmacology
Medical School
University of Massachusetts

H. Kim Lyerly, M.D.

Professor in Surgery, Immunology, Pathology
George Barth Geller Chair of Cancer Research
Director of the Center of Applied Therapeutics
Duke Cancer Institute
Duke University Medical Center

Frank Maldarelli, M.D., Ph.D.

Investigator
HIV DRP Host-Virus Interaction Branch
National Cancer Institute
National Institutes of Health

David M. Margolis, M.D.

Professor of Medicine, Microbiology and
Immunology, and Epidemiology
School of Medicine
University of North Carolina at Chapel Hill

Martin H. Markowitz, M.D.

Professor and Clinical Director
Aaron Diamond AIDS Research Center

Javier Martinez-Picado, Ph.D.*

Catalan Institute for Research and Advanced
Studies Research Professor
AIDS Research Institute IrsiCaixa

Kenneth Hugh Mayer, M.D.

Infectious Disease Attending & Director of HIV
Prevention Research
Beth Israel Deaconess Medical Center
Professor of Medicine
Harvard Medical School
Medical Research Director, Co-Chair
The Fenway Institute/Fenway Health

Joseph M. McCune, M.D., Ph.D.

Professor of Medicine
Department of Medicine
University of California, San Francisco

Olivier Van Der Meeren, M.D.*

Research & Development
GlaxoSmithKline

Donna Mildvan, M.D.

Chief, Division of Infectious Diseases
Department of Medicine
Beth Israel Medical Center

Hoi Ping Mok, Ph.D.*

Department of Medicine
University of Cambridge

Daniela Monaco, Ph.D.*

Postdoctoral Fellow
Yerkes National Primate Research Center with
Emory Vaccine Center
Emory University

Godwin Nchinda, Ph.D.*

Professor
Senior Immunologist
Head of Vaccinology/Biobanking Laboratory
Deputy Director General CIRCB
Chantal Biya International Reference Center for
Research on the Prevention and Management
of HIV/AIDS

Jay A. Nelson, Ph.D.

Professor and Director
Vaccine and Gene Therapy Institute
Oregon Health and Science University

Douglas Nixon, M.D., Ph.D.*

Professor of Immunology in Medicine
Weill Medical College of Cornell University

David O'Connor, Ph.D.*

Professor
Department of Pathology and Laboratory
Medicine
University of Wisconsin-Madison

Nancy Padian, Ph.D., M.P.H.

Adjunct Professor of Epidemiology
School of Public Health
University of California, Berkeley

Savita Pahwa, M.D.

Professor of Microbiology and Immunology
Professor in Pediatrics and Medicine
Director of the Miami Center for AIDS Research
University of Miami Leonard M. Miller School of
Medicine

Tristram G. Parslow, M.D., Ph.D.

William Patterson Timmie Professor and Chair
Department of Pathology and Laboratory
Medicine
Emory University School of Medicine

Deborah Persaud, M.D.*

Professor
School of Medicine
Pediatric Infectious Disease
Bloomberg School of Public Health
Microbiology and Molecular Immunology
Johns Hopkins University

Matija Peterlin, M.D.

Professor of Medicine, Microbiology and Immunology
Department of Medicine
University of California, San Francisco

Christopher Peterson, Ph.D.*

Staff Scientist
Fred Hutchinson Cancer Research Center

Lynn Pulliam, Ph.D.

Professor
Department of Laboratory Medicine and Medicine
University of California, San Francisco
Veterans Affairs Medical Center

Reena Rajasuriar, Ph.D.*

Pharmacy Lecturer
University of Malaya

Christina Ramirez, Ph.D.*

Professor of Biostatistics
Fielding School of Public Health
University of California, Los Angeles

Lee Ratner, M.D., Ph.D.

Professor
Department of Medicine
Washington University School of Medicine

Roger Keith Reeves, Ph.D.*

Associate Professor of Medicine
Harvard Medical School
Ragon Institute of MGH, MIT, and Harvard
Director, Harvard CFAR Advanced Laboratory Technologies Core
Center for Virology and Vaccine Research
Beth Israel Deaconess Medical Center

Andrew Rice, Ph.D.

Professor
Department of Molecular Virology and Microbiology
Baylor College of Medicine

Nadia Roan, Ph.D.*

Associate Professor
Department of Urology
University of California, San Francisco

Melissa Robbiani, Ph.D.

Senior Scientist and Director of Biomedical HIV Research
Center for Biomedical Research
Population Council

Mitchell Rosner, M.D.*

Henry B. Mulholland Professor of Medicine
Chair, Department of Medicine
University of Virginia

Ruth M. Ruprecht, M.D., Ph.D.

Scientist, Department of Virology and Immunology
Southwest National Primate Research Center
Director, Texas Biomed AIDS Research Program
Texas Biomedical Research Institute

Timothy Schacker, M.D.*

Vice Dean for Research, Medical School
Director, Program in HIV Medicine
Director, Clinical Translational Research Services,
Clinical and Translational Science Institute (CTSI)
Professor of Medicine, Division of Infectious Diseases and International Medicine
University of Minnesota

Joshua Schiffer, M.D.*

Associate Member
Vaccine and Infectious Disease Division
Associate Member
Clinical Research Division
Fred Hutchinson Cancer Research Center

Frederick A. Schmitt, Ph.D.

Professor
Departments of Neurology, Psychiatry, and Psychology and Behavioral Science
Sanders Brown Center on Aging
University of Kentucky

Gerald Schochetman, Ph.D.

Senior Director
Diagnostics Research
Abbott Laboratories

Sagi Shapira, Ph.D.*

Assistant Professor of Systems Biology
Department of Microbiology & Immunology
Columbia University

Alex Sigal, Ph.D.*

Group Leader, Max Planck Institute for Infection Biology
Africa Health Research Institute (AHRI)

Viviana Simon, M.D., Ph.D.*

Professor
Department of Microbiology
Department of Medicine, Infectious Diseases
Icahn School of Medicine at Mount Sinai

Gail Skowron, M.D.

Professor of Medicine
Boston University School of Medicine

Natalia Soriano-Sarabia, Ph.D.*

Assistant Professor
Department Microbiology, Immunology and Tropical Medicine
School of Medicine and Health Sciences
The George Washington University

Leonidas Stamatatos, Ph.D.

Member
Fred Hutchinson Cancer Research Center
Vaccine and Infectious Disease Division
Immunology and Vaccine Development Program

Spyridon Stavrou, Ph.D.*

Assistant Professor
Department of Microbiology and Immunology
Jacobs School of Medicine & Biomedical Sciences
State University of New York at Buffalo

Kathryn Stephenson, M.D.*

Assistant Professor of Medicine
Department of Medicine
Beth Israel Deaconess Medical Center

Mario Stevenson, Ph.D.

Professor of Medicine
Chief, Division of Infectious Diseases
University of Miami Leonard M. Miller School of Medicine

Lydie Trautmann, Eng.D., Ph.D.*

Chief
Cellular Immunology Section
U.S. Military HIV Research Program

Sebastien Viel, PharmD, Ph.D.*

Visiting Associate Professor
Department of Pediatrics
Stanford University

David Vlahov, Ph.D., R.N.

Professor of Nursing,
Epidemiology, and Biostatistics
University of California, San Francisco

David J. Volsky, Ph.D.

Professor of Medicine and Pathology
Icahn School of Medicine at Mount Sinai
Director of Molecular Virology Laboratory
Department of Medicine
Mount Sinai St. Luke's and Roosevelt Hospitals

Angela Wahl, Ph.D.*

Assistant Professor
Division of Infectious Diseases
UNC School of Medicine

Misaki Wayengera, MBChB., MSc Immunology, Ph.D.*

Department of Pathology
College of Health Sciences
Makerere University

Steven S. Witkin, Ph.D.

Professor of Immunology
Department of Obstetrics and Gynecology
Weill Cornell Medical College

Peter R. Wolfe, M.D.

Associate Clinical Professor
David Geffen School of Medicine
University of California, Los Angeles
Sub-Investigator
Ruane Clinical Research

Kim Woodrow, Ph.D.*

Associate Professor
Department of Bioengineering
University of Washington

Richard T. Wyatt, Ph.D.

Professor of Immunology
IAVI Center for Neutralizing Antibodies
The Scripps Research Institute

Gert van Zyl, Ph.D.*

Associate Professor
Division of Medical Virology
Department of Pathology
Faculty of Medicine & Health Sciences
Stellenbosch University

PROGRAM ADVISORY COUNCIL

Mervyn F. Silverman, M.D., M.P.H. (Chairman)
President
Mervyn F. Silverman Associates
Crockett, CA

Judith D. Auerbach, Ph.D.
Science and Policy Consultant, and Professor
School of Medicine
University of California, San Francisco

David Bloom, Ph.D.
Clarence James Gamble Professor of Economics
and Demography
Department of Global Health and Population
Harvard T.H. Chan School of Public Health
Boston, MA

Tim Brown, Ph.D.
Senior Fellow
The East-West Center
Honolulu, HI

Daniel Douek, M.D., Ph.D.
Chief, Human Immunology Section
Vaccine Research Center
National Institute of Allergy and Infectious
Diseases
National Institutes of Health

Daria J. Hazuda, Ph.D.
Vice President, Scientific Affairs for Infectious
Disease
Merck & Company, Inc.
West Point, PA

Katherine Luzuriaga, M.D.
Professor, Molecular Medicine, Pediatrics
and Medicine
University of Massachusetts Medical School
Worcester, MA

Kenneth H. Mayer, M.D.
Infectious Disease Attending and Director of HIV
Prevention Research
Beth Israel Deaconess Medical Center

Professor of Medicine
Harvard Medical School

Medical Research Director and Co-Chair
The Fenway Institute/Fenway Health

Jeffrey L. Sturchio, Ph.D.
President and Chief Executive Officer
Rabin Martin, NYC

Visiting Scholar
The Institute for Applied Economics, Global Health
and the Study of Business Enterprise
Johns Hopkins University

Member
The Council on Foreign Relations

Phill Wilson
Member
amfAR Board of Trustees

Founder and Chief Executive Officer (Retired)
The Black AIDS Institute
Los Angeles, CA

MANAGEMENT GROUP

Kevin Robert Frost
Chief Executive Officer

Anthony Ancona
Vice President and Director, Human Resources

Susan J. Blumenthal, M.D., M.P.A.
Senior Policy and Medical Advisor

Kyle Clifford
Vice President, Development
(June 2020—present)

Bradley Jensen
Chief Financial Officer

Rowena Johnston, Ph.D.
Vice President and Director, Research

Jeffrey Laurence, M.D.
Senior Scientific Consultant for Programs

Gregorio Millett, M.P.H.
Vice President and Director, Public Policy

Eric Muscatell
Vice President, Development
(through May 2020)

AnnMari Shannahan
Vice President, Public Information

Annette Sohn, M.D.
Vice President and Director, TREAT Asia

amfAR, The Foundation for AIDS Research

NEW YORK

120 Wall Street, 13th Floor
New York, NY 10005-3908
(212) 806-1600 (tel)
(212) 806-1601 (fax)

WASHINGTON, D.C.

1100 Vermont Avenue, NW
Suite 600
Washington, DC 20005
(202) 331-8600 (tel)
(202) 331-8606 (fax)

BANGKOK, THAILAND

TREAT Asia
Exchange Tower
388 Sukhumvit Road, Suite 2104
Klongtoey, Bangkok 10110
Thailand
+66 (0)2 663 7561 (tel)
+66 (0)2 663 7562 (fax)

www.amfar.org



amfAR meets the BBB
Wise Giving Alliance's
Standards for Charity
Accountability.

